КОМБИНАЦИЯ 4-{ 3-[ЦИС-ГЕКСАГИДРОЦИКЛОПЕНТА[C]ПИРРОЛ-2(1Н)-ИЛ]ПРОПОКСИ} БЕНЗАМИДА И АНТАГОНИСТА NMDA-РЕЦЕПТОРА И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
1. A combination of 4- {3- [cis-hexahydrocyclopenta [c] pyrrol-2 (1H) -yl] propoxy} benzamide of formula (I): or a salt thereof with a pharmaceutically acceptable acid or base, and an antagonist of NMDA-glutamate retseptora.2 . Combination according to Claim. 1, characterized in that 4- {3- [cis-hexahydrocyclopenta [c] pyrrol-2 (1H) -yl] propoxy} benzamide used in the form of oxalate or gidrohlorida.3. Combination according to Claim. 1 or 2, wherein the antagonist of NMDA-glutamate receptor represents memantin.4. Combination according to Claim. 1 or 2, wherein memantine is administered in the form gidrohlorida.5. . A combination according to claim 1 or 2, for use as a medicament, wherein: (I) 4- {3- [cis-hexahydrocyclopenta [c] pyrrol-2 (1H) -yl] propoxy} benzamide is administered in a daily dose of 2 mg 5 mg or 20 mg (calculated as base equivalent) in hydrochloride form, and (II) an antagonist of NMDA-glutamate receptor is memantine hydrochloride, which is administered in a daily dose of 10 mg or 20 mg.6. A pharmaceutical composition which comprises as active ingredient 4- {3- [cis-hexahydrocyclopenta [c] pyrrol-2 (1H) -yl] propoxy} benzamide or a salt thereof with a pharmaceutically acceptable acid or base, in combination with an antagonist of glutamate NMDA- receptor of claim. 1-4, in combination with one or more pharmaceutically acceptable auxiliaries veschestvami.7. A pharmaceutical composition according to claim. 6 for use in treating cognitive disorders associated with cerebral aging and neurodegenerative zabolevaniyami.8. A pharmaceutical composition for use according to claim. 7 in the treatment of cognitive impairment associated with the disease Altsgeymera.9. A pharmaceutical composition according to claim. 6 differs1. Комбинация 4-{3-[цис-гексагидроциклопента[с]пиррол-2(1H)-ил]пропокси}бензамида формулы (I):или его соли присоединения фармацевтически приемлемой кислоты или основания, и антагониста глутаматного NMDA-рецептора.2. Комбинация по п. 1, отличаю
